 | • レポートコード：QY2112C03908 • 出版社/出版日：QYResearch / 2021年12月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品 |
| Single User | ￥735,000 (USD4,900) | ▷ お問い合わせ |
| Multi User | ￥1,102,500 (USD7,350) | ▷ お問い合わせ |
| Enterprise License | ￥1,470,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査資料は物理的解毒剤の世界市場の現状について調査・分析し、2027年までの市場を予測しました。物理的解毒剤の世界市場概要、メーカー別の競争状況と市場シェア、種類別市場規模（注射、錠剤、その他）、用途別市場規模（農薬中毒、重金属中毒、動物咬傷中毒、シアン化物中毒、その他）、主要地域別市場規模（北米・アメリカ、ヨーロッパ、アジア・日本・中国・インド、中南米、中東・アフリカ）、関連企業の情報、バリューチェーン・販売チャネル、市場動向などを収録しています。 ・物理的解毒剤の世界市場概要 ・メーカー別の競争状況、市場シェア ・物理的解毒剤の種類別市場規模：注射、錠剤、その他 ・物理的解毒剤の用途別市場規模：農薬中毒、重金属中毒、動物咬傷中毒、シアン化物中毒、その他 ・北米の物理的解毒剤市場規模2016-2027：種類別、用途別、国別（アメリカ、カナダ） ・ヨーロッパの物理的解毒剤市場規模2016-2027：種類別、用途別、国別（ドイツ、フランス、イギリス） ・アジアの物理的解毒剤市場規模2016-2027：種類別、用途別、国別（日本、中国、インド、韓国） ・中南米の物理的解毒剤市場規模2016-2027：種類別、用途別、国別（メキシコ、ブラジル） ・中東・アフリカの物理的解毒剤市場規模2016-2027：種類別、用途別、国別（トルコ、サウジアラビア） ・企業情報：Roche、Pfizer、Bayer、Johnson & Johnson、Novartis、Eli Lilly、Teva、Boehringer Ingelheim、Mylan、Fresenius Kabi、Baxter、Furen Pharmaceutical、GSK、Viatris ・物理的解毒剤のバリューチェーン・販売チャネル分析 ・物理的解毒剤の世界市場動向 |
Physical antidotes which prevent the absorption of poison into the body. a) Adsorbing: The main example is activated charcoal. b) Coating: A mixture of egg & milk make a coat over the mucosa. c) Dissolving: 10% alcohol or glycine for carbolic acid.
Market Analysis and Insights: Global Physical Antidotes Market
The global Physical Antidotes market is valued at US$ XX million in 2020. The market size will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.
Global Physical Antidotes Scope and Segment
Physical Antidotes market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Physical Antidotes market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.
Segment by Type
Injection
Tablet
Others
Segment by Application
Pesticide Poisoning
Heavy Metal Poisoning
Animal Bites Poisoning
Cyanide Poisoning
Others
By Company
Roche
Pfizer
Bayer
Johnson & Johnson
Novartis
Eli Lilly
Teva
Boehringer Ingelheim
Mylan
Fresenius Kabi
Baxter
Furen Pharmaceutical
GSK
Viatris
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
1 Study Coverage
1.1 Physical Antidotes Product Introduction
1.2 Market by Type
1.2.1 Global Physical Antidotes Market Size Growth Rate by Type
1.2.2 Injection
1.2.3 Tablet
1.2.4 Others
1.3 Market by Application
1.3.1 Global Physical Antidotes Market Size Growth Rate by Application
1.3.2 Pesticide Poisoning
1.3.3 Heavy Metal Poisoning
1.3.4 Animal Bites Poisoning
1.3.5 Cyanide Poisoning
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Physical Antidotes Sales Estimates and Forecasts 2016-2027
2.2 Global Physical Antidotes Revenue Estimates and Forecasts 2016-2027
2.3 Global Physical Antidotes Revenue by Region: 2016 VS 2021 VS 2027
2.4 Global Top Physical Antidotes Regions by Sales
2.4.1 Global Top Physical Antidotes Regions by Sales (2016-2021)
2.4.2 Global Top Physical Antidotes Regions by Sales (2022-2027)
2.5 Global Top Physical Antidotes Regions by Revenue
2.5.1 Global Top Physical Antidotes Regions by Revenue (2016-2021)
2.5.2 Global Top Physical Antidotes Regions by Revenue (2022-2027)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Physical Antidotes Sales by Manufacturers
3.1.1 Global Top Physical Antidotes Manufacturers by Sales (2016-2021)
3.1.2 Global Top Physical Antidotes Manufacturers Market Share by Sales (2016-2021)
3.1.3 Global Top 10 and Top 5 Companies by Physical Antidotes Sales in 2020
3.2 Global Physical Antidotes Revenue by Manufacturers
3.2.1 Global Top Physical Antidotes Manufacturers by Revenue (2016-2021)
3.2.2 Global Top Physical Antidotes Manufacturers Market Share by Revenue (2016-2021)
3.2.3 Global Top 10 and Top 5 Companies by Physical Antidotes Revenue in 2020
3.3 Global Physical Antidotes Sales Price by Manufacturers
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Physical Antidotes Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Physical Antidotes Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Physical Antidotes Sales by Type
4.1.1 Global Physical Antidotes Historical Sales by Type (2016-2021)
4.1.2 Global Physical Antidotes Forecasted Sales by Type (2022-2027)
4.1.3 Global Physical Antidotes Sales Market Share by Type (2016-2027)
4.2 Global Physical Antidotes Revenue by Type
4.2.1 Global Physical Antidotes Historical Revenue by Type (2016-2021)
4.2.2 Global Physical Antidotes Forecasted Revenue by Type (2022-2027)
4.2.3 Global Physical Antidotes Revenue Market Share by Type (2016-2027)
4.3 Global Physical Antidotes Price by Type
4.3.1 Global Physical Antidotes Price by Type (2016-2021)
4.3.2 Global Physical Antidotes Price Forecast by Type (2022-2027)
5 Market Size by Application
5.1 Global Physical Antidotes Sales by Application
5.1.1 Global Physical Antidotes Historical Sales by Application (2016-2021)
5.1.2 Global Physical Antidotes Forecasted Sales by Application (2022-2027)
5.1.3 Global Physical Antidotes Sales Market Share by Application (2016-2027)
5.2 Global Physical Antidotes Revenue by Application
5.2.1 Global Physical Antidotes Historical Revenue by Application (2016-2021)
5.2.2 Global Physical Antidotes Forecasted Revenue by Application (2022-2027)
5.2.3 Global Physical Antidotes Revenue Market Share by Application (2016-2027)
5.3 Global Physical Antidotes Price by Application
5.3.1 Global Physical Antidotes Price by Application (2016-2021)
5.3.2 Global Physical Antidotes Price Forecast by Application (2022-2027)
6 North America
6.1 North America Physical Antidotes Market Size by Type
6.1.1 North America Physical Antidotes Sales by Type (2016-2027)
6.1.2 North America Physical Antidotes Revenue by Type (2016-2027)
6.2 North America Physical Antidotes Market Size by Application
6.2.1 North America Physical Antidotes Sales by Application (2016-2027)
6.2.2 North America Physical Antidotes Revenue by Application (2016-2027)
6.3 North America Physical Antidotes Market Size by Country
6.3.1 North America Physical Antidotes Sales by Country (2016-2027)
6.3.2 North America Physical Antidotes Revenue by Country (2016-2027)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Physical Antidotes Market Size by Type
7.1.1 Europe Physical Antidotes Sales by Type (2016-2027)
7.1.2 Europe Physical Antidotes Revenue by Type (2016-2027)
7.2 Europe Physical Antidotes Market Size by Application
7.2.1 Europe Physical Antidotes Sales by Application (2016-2027)
7.2.2 Europe Physical Antidotes Revenue by Application (2016-2027)
7.3 Europe Physical Antidotes Market Size by Country
7.3.1 Europe Physical Antidotes Sales by Country (2016-2027)
7.3.2 Europe Physical Antidotes Revenue by Country (2016-2027)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Physical Antidotes Market Size by Type
8.1.1 Asia Pacific Physical Antidotes Sales by Type (2016-2027)
8.1.2 Asia Pacific Physical Antidotes Revenue by Type (2016-2027)
8.2 Asia Pacific Physical Antidotes Market Size by Application
8.2.1 Asia Pacific Physical Antidotes Sales by Application (2016-2027)
8.2.2 Asia Pacific Physical Antidotes Revenue by Application (2016-2027)
8.3 Asia Pacific Physical Antidotes Market Size by Region
8.3.1 Asia Pacific Physical Antidotes Sales by Region (2016-2027)
8.3.2 Asia Pacific Physical Antidotes Revenue by Region (2016-2027)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Physical Antidotes Market Size by Type
9.1.1 Latin America Physical Antidotes Sales by Type (2016-2027)
9.1.2 Latin America Physical Antidotes Revenue by Type (2016-2027)
9.2 Latin America Physical Antidotes Market Size by Application
9.2.1 Latin America Physical Antidotes Sales by Application (2016-2027)
9.2.2 Latin America Physical Antidotes Revenue by Application (2016-2027)
9.3 Latin America Physical Antidotes Market Size by Country
9.3.1 Latin America Physical Antidotes Sales by Country (2016-2027)
9.3.2 Latin America Physical Antidotes Revenue by Country (2016-2027)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Physical Antidotes Market Size by Type
10.1.1 Middle East and Africa Physical Antidotes Sales by Type (2016-2027)
10.1.2 Middle East and Africa Physical Antidotes Revenue by Type (2016-2027)
10.2 Middle East and Africa Physical Antidotes Market Size by Application
10.2.1 Middle East and Africa Physical Antidotes Sales by Application (2016-2027)
10.2.2 Middle East and Africa Physical Antidotes Revenue by Application (2016-2027)
10.3 Middle East and Africa Physical Antidotes Market Size by Country
10.3.1 Middle East and Africa Physical Antidotes Sales by Country (2016-2027)
10.3.2 Middle East and Africa Physical Antidotes Revenue by Country (2016-2027)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Overview
11.1.3 Roche Physical Antidotes Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Roche Physical Antidotes Product Description
11.1.5 Roche Recent Developments
11.2 Pfizer
11.2.1 Pfizer Corporation Information
11.2.2 Pfizer Overview
11.2.3 Pfizer Physical Antidotes Sales, Price, Revenue and Gross Margin (2016-2021)
11.2.4 Pfizer Physical Antidotes Product Description
11.2.5 Pfizer Recent Developments
11.3 Bayer
11.3.1 Bayer Corporation Information
11.3.2 Bayer Overview
11.3.3 Bayer Physical Antidotes Sales, Price, Revenue and Gross Margin (2016-2021)
11.3.4 Bayer Physical Antidotes Product Description
11.3.5 Bayer Recent Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Corporation Information
11.4.2 Johnson & Johnson Overview
11.4.3 Johnson & Johnson Physical Antidotes Sales, Price, Revenue and Gross Margin (2016-2021)
11.4.4 Johnson & Johnson Physical Antidotes Product Description
11.4.5 Johnson & Johnson Recent Developments
11.5 Novartis
11.5.1 Novartis Corporation Information
11.5.2 Novartis Overview
11.5.3 Novartis Physical Antidotes Sales, Price, Revenue and Gross Margin (2016-2021)
11.5.4 Novartis Physical Antidotes Product Description
11.5.5 Novartis Recent Developments
11.6 Eli Lilly
11.6.1 Eli Lilly Corporation Information
11.6.2 Eli Lilly Overview
11.6.3 Eli Lilly Physical Antidotes Sales, Price, Revenue and Gross Margin (2016-2021)
11.6.4 Eli Lilly Physical Antidotes Product Description
11.6.5 Eli Lilly Recent Developments
11.7 Teva
11.7.1 Teva Corporation Information
11.7.2 Teva Overview
11.7.3 Teva Physical Antidotes Sales, Price, Revenue and Gross Margin (2016-2021)
11.7.4 Teva Physical Antidotes Product Description
11.7.5 Teva Recent Developments
11.8 Boehringer Ingelheim
11.8.1 Boehringer Ingelheim Corporation Information
11.8.2 Boehringer Ingelheim Overview
11.8.3 Boehringer Ingelheim Physical Antidotes Sales, Price, Revenue and Gross Margin (2016-2021)
11.8.4 Boehringer Ingelheim Physical Antidotes Product Description
11.8.5 Boehringer Ingelheim Recent Developments
11.9 Mylan
11.9.1 Mylan Corporation Information
11.9.2 Mylan Overview
11.9.3 Mylan Physical Antidotes Sales, Price, Revenue and Gross Margin (2016-2021)
11.9.4 Mylan Physical Antidotes Product Description
11.9.5 Mylan Recent Developments
11.10 Fresenius Kabi
11.10.1 Fresenius Kabi Corporation Information
11.10.2 Fresenius Kabi Overview
11.10.3 Fresenius Kabi Physical Antidotes Sales, Price, Revenue and Gross Margin (2016-2021)
11.10.4 Fresenius Kabi Physical Antidotes Product Description
11.10.5 Fresenius Kabi Recent Developments
11.11 Baxter
11.11.1 Baxter Corporation Information
11.11.2 Baxter Overview
11.11.3 Baxter Physical Antidotes Sales, Price, Revenue and Gross Margin (2016-2021)
11.11.4 Baxter Physical Antidotes Product Description
11.11.5 Baxter Recent Developments
11.12 Furen Pharmaceutical
11.12.1 Furen Pharmaceutical Corporation Information
11.12.2 Furen Pharmaceutical Overview
11.12.3 Furen Pharmaceutical Physical Antidotes Sales, Price, Revenue and Gross Margin (2016-2021)
11.12.4 Furen Pharmaceutical Physical Antidotes Product Description
11.12.5 Furen Pharmaceutical Recent Developments
11.13 GSK
11.13.1 GSK Corporation Information
11.13.2 GSK Overview
11.13.3 GSK Physical Antidotes Sales, Price, Revenue and Gross Margin (2016-2021)
11.13.4 GSK Physical Antidotes Product Description
11.13.5 GSK Recent Developments
11.14 Viatris
11.14.1 Viatris Corporation Information
11.14.2 Viatris Overview
11.14.3 Viatris Physical Antidotes Sales, Price, Revenue and Gross Margin (2016-2021)
11.14.4 Viatris Physical Antidotes Product Description
11.14.5 Viatris Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Physical Antidotes Value Chain Analysis
12.2 Physical Antidotes Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Physical Antidotes Production Mode & Process
12.4 Physical Antidotes Sales and Marketing
12.4.1 Physical Antidotes Sales Channels
12.4.2 Physical Antidotes Distributors
12.5 Physical Antidotes Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Physical Antidotes Industry Trends
13.2 Physical Antidotes Market Drivers
13.3 Physical Antidotes Market Challenges
13.4 Physical Antidotes Market Restraints
14 Key Findings in The Global Physical Antidotes Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Table 1. Global Physical Antidotes Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Injection
Table 3. Major Manufacturers of Tablet
Table 4. Major Manufacturers of Others
Table 5. Global Physical Antidotes Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million)
Table 6. Global Physical Antidotes Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
Table 7. Global Physical Antidotes Sales by Region (2016-2021) & (K Units)
Table 8. Global Physical Antidotes Sales Market Share by Region (2016-2021)
Table 9. Global Physical Antidotes Sales by Region (2022-2027) & (K Units)
Table 10. Global Physical Antidotes Sales Market Share by Region (2022-2027)
Table 11. Global Physical Antidotes Revenue by Region (2016-2021) & (US$ Million)
Table 12. Global Physical Antidotes Revenue Market Share by Region (2016-2021)
Table 13. Global Physical Antidotes Revenue by Region (2022-2027) & (US$ Million)
Table 14. Global Physical Antidotes Revenue Market Share by Region (2022-2027)
Table 15. Global Physical Antidotes Sales by Manufacturers (2016-2021) & (K Units)
Table 16. Global Physical Antidotes Sales Share by Manufacturers (2016-2021)
Table 17. Global Physical Antidotes Revenue by Manufacturers (2016-2021) & (US$ Million)
Table 18. Global Physical Antidotes Revenue Share by Manufacturers (2016-2021)
Table 19. Physical Antidotes Price by Manufacturers 2016-2021 (US$/Unit)
Table 20. Global Physical Antidotes Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Physical Antidotes by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Physical Antidotes as of 2020)
Table 22. Physical Antidotes Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Physical Antidotes Product Offered
Table 24. Date of Manufacturers Enter into Physical Antidotes Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Physical Antidotes Sales by Type (2016-2021) & (K Units)
Table 27. Global Physical Antidotes Sales by Type (2022-2027) & (K Units)
Table 28. Global Physical Antidotes Sales Share by Type (2016-2021)
Table 29. Global Physical Antidotes Sales Share by Type (2022-2027)
Table 30. Global Physical Antidotes Revenue by Type (2016-2021) & (US$ Million)
Table 31. Global Physical Antidotes Revenue by Type (2022-2027) & (US$ Million)
Table 32. Global Physical Antidotes Revenue Share by Type (2016-2021)
Table 33. Global Physical Antidotes Revenue Share by Type (2022-2027)
Table 34. Physical Antidotes Price by Type (2016-2021) & (US$/Unit)
Table 35. Global Physical Antidotes Price Forecast by Type (2022-2027) & (US$/Unit)
Table 36. Global Physical Antidotes Sales by Application (2016-2021) & (K Units)
Table 37. Global Physical Antidotes Sales by Application (2022-2027) & (K Units)
Table 38. Global Physical Antidotes Sales Share by Application (2016-2021)
Table 39. Global Physical Antidotes Sales Share by Application (2022-2027)
Table 40. Global Physical Antidotes Revenue by Application (2016-2021) & (US$ Million)
Table 41. Global Physical Antidotes Revenue by Application (2022-2027) & (US$ Million)
Table 42. Global Physical Antidotes Revenue Share by Application (2016-2021)
Table 43. Global Physical Antidotes Revenue Share by Application (2022-2027)
Table 44. Physical Antidotes Price by Application (2016-2021) & (US$/Unit)
Table 45. Global Physical Antidotes Price Forecast by Application (2022-2027) & (US$/Unit)
Table 46. North America Physical Antidotes Sales by Type (2016-2021) & (K Units)
Table 47. North America Physical Antidotes Sales by Type (2022-2027) & (K Units)
Table 48. North America Physical Antidotes Revenue by Type (2016-2021) & (US$ Million)
Table 49. North America Physical Antidotes Revenue by Type (2022-2027) & (US$ Million)
Table 50. North America Physical Antidotes Sales by Application (2016-2021) & (K Units)
Table 51. North America Physical Antidotes Sales by Application (2022-2027) & (K Units)
Table 52. North America Physical Antidotes Revenue by Application (2016-2021) & (US$ Million)
Table 53. North America Physical Antidotes Revenue by Application (2022-2027) & (US$ Million)
Table 54. North America Physical Antidotes Sales by Country (2016-2021) & (K Units)
Table 55. North America Physical Antidotes Sales by Country (2022-2027) & (K Units)
Table 56. North America Physical Antidotes Revenue by Country (2016-2021) & (US$ Million)
Table 57. North America Physical Antidotes Revenue by Country (2022-2027) & (US$ Million)
Table 58. Europe Physical Antidotes Sales by Type (2016-2021) & (K Units)
Table 59. Europe Physical Antidotes Sales by Type (2022-2027) & (K Units)
Table 60. Europe Physical Antidotes Revenue by Type (2016-2021) & (US$ Million)
Table 61. Europe Physical Antidotes Revenue by Type (2022-2027) & (US$ Million)
Table 62. Europe Physical Antidotes Sales by Application (2016-2021) & (K Units)
Table 63. Europe Physical Antidotes Sales by Application (2022-2027) & (K Units)
Table 64. Europe Physical Antidotes Revenue by Application (2016-2021) & (US$ Million)
Table 65. Europe Physical Antidotes Revenue by Application (2022-2027) & (US$ Million)
Table 66. Europe Physical Antidotes Sales by Country (2016-2021) & (K Units)
Table 67. Europe Physical Antidotes Sales by Country (2022-2027) & (K Units)
Table 68. Europe Physical Antidotes Revenue by Country (2016-2021) & (US$ Million)
Table 69. Europe Physical Antidotes Revenue by Country (2022-2027) & (US$ Million)
Table 70. Asia Pacific Physical Antidotes Sales by Type (2016-2021) & (K Units)
Table 71. Asia Pacific Physical Antidotes Sales by Type (2022-2027) & (K Units)
Table 72. Asia Pacific Physical Antidotes Revenue by Type (2016-2021) & (US$ Million)
Table 73. Asia Pacific Physical Antidotes Revenue by Type (2022-2027) & (US$ Million)
Table 74. Asia Pacific Physical Antidotes Sales by Application (2016-2021) & (K Units)
Table 75. Asia Pacific Physical Antidotes Sales by Application (2022-2027) & (K Units)
Table 76. Asia Pacific Physical Antidotes Revenue by Application (2016-2021) & (US$ Million)
Table 77. Asia Pacific Physical Antidotes Revenue by Application (2022-2027) & (US$ Million)
Table 78. Asia Pacific Physical Antidotes Sales by Region (2016-2021) & (K Units)
Table 79. Asia Pacific Physical Antidotes Sales by Region (2022-2027) & (K Units)
Table 80. Asia Pacific Physical Antidotes Revenue by Region (2016-2021) & (US$ Million)
Table 81. Asia Pacific Physical Antidotes Revenue by Region (2022-2027) & (US$ Million)
Table 82. Latin America Physical Antidotes Sales by Type (2016-2021) & (K Units)
Table 83. Latin America Physical Antidotes Sales by Type (2022-2027) & (K Units)
Table 84. Latin America Physical Antidotes Revenue by Type (2016-2021) & (US$ Million)
Table 85. Latin America Physical Antidotes Revenue by Type (2022-2027) & (US$ Million)
Table 86. Latin America Physical Antidotes Sales by Application (2016-2021) & (K Units)
Table 87. Latin America Physical Antidotes Sales by Application (2022-2027) & (K Units)
Table 88. Latin America Physical Antidotes Revenue by Application (2016-2021) & (US$ Million)
Table 89. Latin America Physical Antidotes Revenue by Application (2022-2027) & (US$ Million)
Table 90. Latin America Physical Antidotes Sales by Country (2016-2021) & (K Units)
Table 91. Latin America Physical Antidotes Sales by Country (2022-2027) & (K Units)
Table 92. Latin America Physical Antidotes Revenue by Country (2016-2021) & (US$ Million)
Table 93. Latin America Physical Antidotes Revenue by Country (2022-2027) & (US$ Million)
Table 94. Middle East and Africa Physical Antidotes Sales by Type (2016-2021) & (K Units)
Table 95. Middle East and Africa Physical Antidotes Sales by Type (2022-2027) & (K Units)
Table 96. Middle East and Africa Physical Antidotes Revenue by Type (2016-2021) & (US$ Million)
Table 97. Middle East and Africa Physical Antidotes Revenue by Type (2022-2027) & (US$ Million)
Table 98. Middle East and Africa Physical Antidotes Sales by Application (2016-2021) & (K Units)
Table 99. Middle East and Africa Physical Antidotes Sales by Application (2022-2027) & (K Units)
Table 100. Middle East and Africa Physical Antidotes Revenue by Application (2016-2021) & (US$ Million)
Table 101. Middle East and Africa Physical Antidotes Revenue by Application (2022-2027) & (US$ Million)
Table 102. Middle East and Africa Physical Antidotes Sales by Country (2016-2021) & (K Units)
Table 103. Middle East and Africa Physical Antidotes Sales by Country (2022-2027) & (K Units)
Table 104. Middle East and Africa Physical Antidotes Revenue by Country (2016-2021) & (US$ Million)
Table 105. Middle East and Africa Physical Antidotes Revenue by Country (2022-2027) & (US$ Million)
Table 106. Roche Corporation Information
Table 107. Roche Description and Major Businesses
Table 108. Roche Physical Antidotes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 109. Roche Physical Antidotes Product
Table 110. Roche Recent Developments
Table 111. Pfizer Corporation Information
Table 112. Pfizer Description and Major Businesses
Table 113. Pfizer Physical Antidotes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 114. Pfizer Physical Antidotes Product
Table 115. Pfizer Recent Developments
Table 116. Bayer Corporation Information
Table 117. Bayer Description and Major Businesses
Table 118. Bayer Physical Antidotes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 119. Bayer Physical Antidotes Product
Table 120. Bayer Recent Developments
Table 121. Johnson & Johnson Corporation Information
Table 122. Johnson & Johnson Description and Major Businesses
Table 123. Johnson & Johnson Physical Antidotes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 124. Johnson & Johnson Physical Antidotes Product
Table 125. Johnson & Johnson Recent Developments
Table 126. Novartis Corporation Information
Table 127. Novartis Description and Major Businesses
Table 128. Novartis Physical Antidotes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 129. Novartis Physical Antidotes Product
Table 130. Novartis Recent Developments
Table 131. Eli Lilly Corporation Information
Table 132. Eli Lilly Description and Major Businesses
Table 133. Eli Lilly Physical Antidotes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 134. Eli Lilly Physical Antidotes Product
Table 135. Eli Lilly Recent Developments
Table 136. Teva Corporation Information
Table 137. Teva Description and Major Businesses
Table 138. Teva Physical Antidotes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 139. Teva Physical Antidotes Product
Table 140. Teva Recent Developments
Table 141. Boehringer Ingelheim Corporation Information
Table 142. Boehringer Ingelheim Description and Major Businesses
Table 143. Boehringer Ingelheim Physical Antidotes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 144. Boehringer Ingelheim Physical Antidotes Product
Table 145. Boehringer Ingelheim Recent Developments
Table 146. Mylan Corporation Information
Table 147. Mylan Description and Major Businesses
Table 148. Mylan Physical Antidotes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 149. Mylan Physical Antidotes Product
Table 150. Mylan Recent Developments
Table 151. Fresenius Kabi Corporation Information
Table 152. Fresenius Kabi Description and Major Businesses
Table 153. Fresenius Kabi Physical Antidotes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 154. Fresenius Kabi Physical Antidotes Product
Table 155. Fresenius Kabi Recent Developments
Table 156. Baxter Corporation Information
Table 157. Baxter Description and Major Businesses
Table 158. Baxter Physical Antidotes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 159. Baxter Physical Antidotes Product
Table 160. Baxter Recent Developments
Table 161. Furen Pharmaceutical Corporation Information
Table 162. Furen Pharmaceutical Description and Major Businesses
Table 163. Furen Pharmaceutical Physical Antidotes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 164. Furen Pharmaceutical Physical Antidotes Product
Table 165. Furen Pharmaceutical Recent Developments
Table 166. GSK Corporation Information
Table 167. GSK Description and Major Businesses
Table 168. GSK Physical Antidotes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 169. GSK Physical Antidotes Product
Table 170. GSK Recent Developments
Table 171. Viatris Corporation Information
Table 172. Viatris Description and Major Businesses
Table 173. Viatris Physical Antidotes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 174. Viatris Physical Antidotes Product
Table 175. Viatris Recent Developments
Table 176. Key Raw Materials Lists
Table 177. Raw Materials Key Suppliers Lists
Table 178. Physical Antidotes Distributors List
Table 179. Physical Antidotes Customers List
Table 180. Physical Antidotes Market Trends
Table 181. Physical Antidotes Market Drivers
Table 182. Physical Antidotes Market Challenges
Table 183. Physical Antidotes Market Restraints
Table 184. Research Programs/Design for This Report
Table 185. Key Data Information from Secondary Sources
Table 186. Key Data Information from Primary Sources
List of Figures
Figure 1. Physical Antidotes Product Picture
Figure 2. Global Physical Antidotes Market Share by Type in 2020 & 2027
Figure 3. Injection Product Picture
Figure 4. Tablet Product Picture
Figure 5. Others Product Picture
Figure 6. Global Physical Antidotes Market Share by Application in 2020 & 2027
Figure 7. Pesticide Poisoning
Figure 8. Heavy Metal Poisoning
Figure 9. Animal Bites Poisoning
Figure 10. Cyanide Poisoning
Figure 11. Others
Figure 12. Physical Antidotes Report Years Considered
Figure 13. Global Physical Antidotes Sales 2016-2027 (K Units)
Figure 14. Global Physical Antidotes Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Physical Antidotes Revenue 2016-2027 (US$ Million)
Figure 16. Global Physical Antidotes Revenue Market Share by Region in Percentage: 2020 Versus 2027
Figure 17. Global Physical Antidotes Sales Market Share by Region (2016-2021)
Figure 18. Global Physical Antidotes Sales Market Share by Region (2022-2027)
Figure 19. North America Physical Antidotes Sales YoY (2016-2027) & (K Units)
Figure 20. North America Physical Antidotes Revenue YoY (2016-2027) & (US$ Million)
Figure 21. Europe Physical Antidotes Sales YoY (2016-2027) & (K Units)
Figure 22. Europe Physical Antidotes Revenue YoY (2016-2027) & (US$ Million)
Figure 23. Asia-Pacific Physical Antidotes Sales YoY (2016-2027) & (K Units)
Figure 24. Asia-Pacific Physical Antidotes Revenue YoY (2016-2027) & (US$ Million)
Figure 25. Latin America Physical Antidotes Sales YoY (2016-2027) & (K Units)
Figure 26. Latin America Physical Antidotes Revenue YoY (2016-2027) & (US$ Million)
Figure 27. Middle East & Africa Physical Antidotes Sales YoY (2016-2027) & (K Units)
Figure 28. Middle East & Africa Physical Antidotes Revenue YoY (2016-2027) & (US$ Million)
Figure 29. The Top 10 and Top 5 Players Market Share by Physical Antidotes Sales in 2020
Figure 30. The Top 10 and Top 5 Players Market Share by Physical Antidotes Revenue in 2020
Figure 31. Physical Antidotes Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020
Figure 32. Global Physical Antidotes Sales Market Share by Type (2016-2027)
Figure 33. Global Physical Antidotes Revenue Market Share by Type (2016-2027)
Figure 34. Global Physical Antidotes Sales Market Share by Application (2016-2027)
Figure 35. Global Physical Antidotes Revenue Market Share by Application (2016-2027)
Figure 36. North America Physical Antidotes Sales Market Share by Type (2016-2027)
Figure 37. North America Physical Antidotes Revenue Market Share by Type (2016-2027)
Figure 38. North America Physical Antidotes Sales Market Share by Application (2016-2027)
Figure 39. North America Physical Antidotes Revenue Market Share by Application (2016-2027)
Figure 40. North America Physical Antidotes Sales Share by Country (2016-2027)
Figure 41. North America Physical Antidotes Revenue Share by Country (2016-2027)
Figure 42. United States Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 43. Canada Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 44. Europe Physical Antidotes Sales Market Share by Type (2016-2027)
Figure 45. Europe Physical Antidotes Revenue Market Share by Type (2016-2027)
Figure 46. Europe Physical Antidotes Sales Market Share by Application (2016-2027)
Figure 47. Europe Physical Antidotes Revenue Market Share by Application (2016-2027)
Figure 48. Europe Physical Antidotes Sales Share by Country (2016-2027)
Figure 49. Europe Physical Antidotes Revenue Share by Country (2016-2027)
Figure 50. Germany Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 51. France Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 52. U.K. Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 53. Italy Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 54. Russia Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 55. Asia Pacific Physical Antidotes Sales Market Share by Type (2016-2027)
Figure 56. Asia Pacific Physical Antidotes Revenue Market Share by Type (2016-2027)
Figure 57. Asia Pacific Physical Antidotes Sales Market Share by Application (2016-2027)
Figure 58. Asia Pacific Physical Antidotes Revenue Market Share by Application (2016-2027)
Figure 59. Asia Pacific Physical Antidotes Sales Share by Region (2016-2027)
Figure 60. Asia Pacific Physical Antidotes Revenue Share by Region (2016-2027)
Figure 61. China Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 62. Japan Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 63. South Korea Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 64. India Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 65. Australia Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 66. Taiwan Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 67. Indonesia Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 68. Thailand Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 69. Malaysia Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 70. Latin America Physical Antidotes Sales Market Share by Type (2016-2027)
Figure 71. Latin America Physical Antidotes Revenue Market Share by Type (2016-2027)
Figure 72. Latin America Physical Antidotes Sales Market Share by Application (2016-2027)
Figure 73. Latin America Physical Antidotes Revenue Market Share by Application (2016-2027)
Figure 74. Latin America Physical Antidotes Sales Share by Country (2016-2027)
Figure 75. Latin America Physical Antidotes Revenue Share by Country (2016-2027)
Figure 76. Mexico Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 77. Brazil Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 78. Argentina Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 79. Middle East and Africa Physical Antidotes Sales Market Share by Type (2016-2027)
Figure 80. Middle East and Africa Physical Antidotes Revenue Market Share by Type (2016-2027)
Figure 81. Middle East and Africa Physical Antidotes Sales Market Share by Application (2016-2027)
Figure 82. Middle East and Africa Physical Antidotes Revenue Market Share by Application (2016-2027)
Figure 83. Middle East and Africa Physical Antidotes Sales Share by Country (2016-2027)
Figure 84. Middle East and Africa Physical Antidotes Revenue Share by Country (2016-2027)
Figure 85. Turkey Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 86. Saudi Arabia Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 87. UAE Physical Antidotes Revenue (2016-2027) & (US$ Million)
Figure 88. Physical Antidotes Value Chain
Figure 89. Physical Antidotes Production Process
Figure 90. Channels of Distribution
Figure 91. Distributors Profiles
Figure 92. Bottom-up and Top-down Approaches for This Report
Figure 93. Data Triangulation
Figure 94. Key Executives Interviewed
薬理学的解毒剤のグローバル市場インサイト・予測（～2027年） A drug that has the opposite effect on the body from that caused by a poisonous or toxic substance. Market Analysis and Insights: Global Pharmacological Antidotes Market The global Pharmacological Antidotes market is valued at US$ XX million in 2020. The market size will reach US$ XX million by the …- 金属射出成形用粉末のグローバル市場インサイト・予測（～2027年） Market Analysis and Insights: Global Powders for Metal Injection Moulding Market The global Powders for Metal Injection Moulding market is valued at US$ XX million in 2020. The market size will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027. Global Powders for Met…
- 二次イオン質量分析（SIMS）装置のグローバル市場インサイト・予測（～2027年） Secondary-ion mass spectrometry (SIMS) is a technique used to analyze the composition of solid surfaces and thin films by sputtering the surface of the specimen with a focused primary ion beam and collecting and analyzing ejected secondary ions. The mass/charge ratios of these secondary ions are mea…
- シアン化水素センサーのグローバル市場インサイト・予測（～2027年） Market Analysis and Insights: Global Hydrogen Cyanide Sensor Market The global Hydrogen Cyanide Sensor market is valued at US$ XX million in 2020. The market size will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027. Global Hydrogen Cyanide Sensor Scope and Segment…
- 乳酸菌注射液のグローバル市場インサイト・予測（～2027年） Lactated Ringer’s Injection is a sterile, non-pyrogenic solution intended for fluid and electrolyte replenishment in single dose containers. May be administered intravenously, subcutaneously or intraperitoneally (except in horses) using aseptic technique. Market Analysis and Insights: Global Lactate…